Flexible vs. Fixed Diuretic Regimen in the Management of Chronic Heart Failure: A Pilot Study

Heart Failure Clinical Trial

Official title:

Flexible vs. Fixed Diuretic Regimen in the Management of Chronic Heart Failure: A Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05594823
• Other study ID #: REDA ID: 12724
• Status: Recruiting
• Phase: Phase 4
• Start date: January 3, 2023
• Est. completion date: July 2023

Study information

• Verified date: March 2023
• Source: Lawson Health Research Institute
• Contact: Stuart Smith, MD
• Phone: (519) 663-3428
• Email: stuart.smith[@]lhsc.on.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Heart failure is a major cause of death and hospitalization in Canada. Many of the symptoms experienced by patients with heart failure relate to having fluid accumulate in the lungs causing difficulty breathing, swelling in the legs, and an increase in weight. Thus, one of the cornerstones of managing heart failure includes the use of medications known as diuretics that target the kidneys to reduce fluid accumulation via urination. Deciding on the correct dose of this medication can be quite nuanced as under-dosing can lead to accumulation of fluid, and over-dosing can dehydrate patients and potentially result in lightheadedness/fainting and damage to the kidneys. Currently, options for prescribing diuretics for heart failure include 1) giving patients a regular, fixed dose or 2) having patients monitor their daily weight as a surrogate of their fluid status and then take a dose of diuretic based on a pre-prepared scale. The rationale behind the flexible weight-based diuretic scale is that it can potentially detect early fluid accumulation and thus possibly prevent hospitalization or ED visits, and it also avoids over-dosing and potentially dehydrating patients. Currently, it is not clear whether the flexible diuretic regimen is better than the fixed-dose regimen in preventing ED visits, hospitalizations, kidney damage, or death and as such, this pilot study will directly compare the two commonly used regimens in the management of chronic heart failure patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: July 2023
• Est. primary completion date: July 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosis of heart failure, either reduced (Left ventricular ejection fraction [LVEF] = 40%) or preserved (LVEF > 40%) ejection fraction as measured by echocardiography performed within the last 2 months

2. Prescribed and tolerating furosemide with a minimum daily dose of 40mg oral daily

3. New York Heart Association (NYHA) Class II or higher symptoms

4. NT-proBNP cutoff of = 1000 pg/mL performed within 30 days prior to randomization

5. Age > 18 years

6. English speaking

7. Access to a scale and ability to weigh themselves daily and reliable telephone access

Exclusion Criteria:

1. Myocardial infarction, coronary artery bypass graft surgery, stent insertion and/or angioplasty within 14 days

2. Pregnancy

3. Inability to follow directions and self-monitor as part of a flexible diuretic regimen as discerned by the clinician

4. Allergic reaction to loop diuretics

5. Unable to provide informed consent

Related Conditions & MeSH terms

• Heart Diseases
• Heart Failure

Intervention

Other:
• Ambulatory heart failure management with Flexible Diuretic Regimen with furosemide
Subjects will be given a regimen that determines a variable daily dose of diuretic (furosemide) based on daily self-measured weights as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.
• Ambulatory heart failure management with fixed dose furosemide
Subjects will be prescribed a fixed daily dose of diuretic (furosemide) as part of the standard of care ambulatory management of chronic heart failure. Follow-up will occur at 90 days with routine bloodwork to monitor renal function.

Locations

Country	Name	City	State
Canada	St. Joseph's Health Care	London	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Lawson Health Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality and morbidity composite outcome	Time to first event of a composite outcome including: ambulatory heart failure visit (clinic or emergency department) requiring intravenous diuretic, an increase in oral diuretic dose greater than or equal to 2.5 times their baseline dose prescribed at time of randomization, or the addition of metolazone; hospitalization for heart failure and/or acute kidney injury defined as a serum creatinine > 1.5 times from baseline at time of randomization; and all-cause death up to 90 days post-randomization	90 days
Secondary	Incidence of acute kidney injury	Rate of acute kidney injury defined as a serum creatinine increase of >1.5 times from baseline at 90 days from randomization	90 days
Secondary	Heart Failure Hospitalizations	Total number of hospitalizations due to heart failure (first and recurrent) during the 90 days post-randomization	90 days
Secondary	All-cause Hospitalizations	Total number of hospitalizations for any cause during the 90 days post-randomization	90 days